Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Celgene Corporation    CELG

CELGENE CORPORATION (CELG)
Mes dernières consult.
Most popular
Report
Delayed Quote. Delayed  - 10/20 10:14:59 pm
121.33 USD   -10.76%
10/20 SKECHERS : PayPal and Skechers jump while Celgene tumbles
10/20 NASDAQ 100 MOVE : Celg, pypl
10/20 S&P 500 MOVERS : Celg, pypl
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
 Analysis summary4-Traders Strategies
Summary
  • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
  • The company has poor fundamentals for a short-term investment strategy.
Strengths
  • The current area is a good opportunity for investors interested in buying the stock in a mid or long-term perspective. Indeed, the share is moving closer to its lower bound at USD 112.66 USD in weekly data.
  • The close medium term support offers good timing for purchasing the stock.
  • Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
  • Based on current prices, the company has particularly high valuation levels.
  • For the past seven days, analysts have been lowering their EPS expectations for the company.
Ratings chart
Sector Pharmaceuticals - NEC
1st jan.Capitalisation (M$)Investor Rating
CELGENE CORPORATION18.51%94 923
JOHNSON & JOHNSON23.29%377 585
NOVARTIS13.50%226 453
ROCHE HOLDING LTD.5.55%215 760
PFIZER11.58%213 372
MERCK AND COMPANY7.88%173 214
AMGEN27.41%135 924
SANOFI9.90%125 891
BAYER19.94%115 989
BRISTOL-MYERS SQUIBB COMPAN..10.66%104 463
GLAXOSMITHKLINE-1.66%99 651
NOVO NORDISK A/S24.77%98 848
ABBOTT LABORATORIES45.20%96 897
ELI LILLY AND COMPANY16.56%94 388
ASTRAZENECA16.62%86 419
ALLERGAN PLC-10.89%62 565
More Results
Financials ($)
Sales 2017 13 226 M
EBIT 2017 7 529 M
Net income 2017 4 508 M
Debt 2017 3 949 M
Yield 2017 -
P/E ratio 2017 21,68
P/E ratio 2018 16,66
EV / Sales 2017 7,48x
EV / Sales 2018 6,08x
Capitalization 94 923 M
Surperformance© ratings
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield -
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes
Chart CELGENE CORPORATION
Duration : Period : Day
Celgene Corporation Technical Analysis Chart | CELG | US1510201049 | 4-Traders
Duration : Period : Week
Celgene Corporation Technical Analysis Chart | CELG | US1510201049 | 4-Traders